Henry Schein Intrinsic Value Calculation – Henry Schein Acquires Majority Stake in Ortho Device Maker TriMed
December 21, 2023
🌥️Trending News
Recently, the company has agreed to purchase a majority stake in TriMed, a manufacturer of orthopaedic devices. The strategic purchase of TriMed marks an important milestone for Henry Schein ($NASDAQ:HSIC). It not only gives the company access to a greater variety of orthopaedic products, but also allows it to further expand its presence in the fast-growing orthopaedic market. Furthermore, it positions Henry Schein to capitalize on the aging population, as well as the increasing demand for orthopaedic products.
This move is part of Henry Schein’s larger strategic plan to become a leader in the healthcare industry. Through its acquisition of TriMed, the company has taken a major step towards achieving its goal. It will also continue to look for ways to expand and diversify its product offerings, with a special focus on providing better care and solutions for its customers.
Market Price
On Wednesday, HENRY SCHEIN, a leading global provider of health care products and services, announced that it had acquired a majority stake in TriMed, a medical device manufacturer specializing in orthopaedic and spine products. Following the announcement, HENRY SCHEIN stock opened at $74.3 and closed at $73.4, down by 1.0% from its last closing price of 74.1. The acquisition is set to broaden HENRY SCHEIN’s offering of medical devices, and add TriMed’s cutting-edge orthopaedic and spine products to the HENRY SCHEIN portfolio. It also provides the company with increased opportunities for growth in the medical device market. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Henry Schein. More…
| Total Revenues | Net Income | Net Margin |
| 12.69k | 445 | 4.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Henry Schein. More…
| Operations | Investing | Financing |
| 653 | -276 | -315 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Henry Schein. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 9.15k | 4.14k | 27.26 |
Key Ratios Snapshot
Some of the financial key ratios for Henry Schein are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 9.7% | 12.8% | 5.2% |
| FCF Margin | ROE | ROA |
| 4.2% | 11.7% | 4.6% |
Analysis – Henry Schein Intrinsic Value Calculation
At GoodWhale, we’ve conducted an analysis of HENRY SCHEIN‘s fundamentals and have determined its fair value to be around $82.5. This value was calculated using our proprietary Valuation Line. Currently, HENRY SCHEIN stock is being traded at $73.4, meaning that it is fairly undervalued by 11.1%. Therefore, for those looking to purchase HENRY SCHEIN stock, this might be a good time to buy. More…
Peers
Henry Schein Inc is one of the largest companies in the dental supplies industry.
However, it faces stiff competition from Healthlead PCL, Patterson Companies Inc, and Alfresa Holdings Corp. All four companies are large, international players in the dental supplies industry.
– Healthlead PCL ($SET:HL)
LeadPCL is a Thailand-based company engaged in the manufacture and sale of lead products. The Company offers lead ingots, lead sheets, lead pipes, lead wires, lead oxides and other lead products. It also provides lead recycling services. The Company’s products are used in a range of applications, including in the automotive, electronics, construction and medical industries.
– Patterson Companies Inc ($NASDAQ:PDCO)
Patterson Companies Inc is a leading provider of animal health and dental products and services. The company has a market cap of 2.61B as of 2022 and a return on equity of 16.53%. Patterson Companies Inc operates in the United States, Canada, and Europe. The company’s products and services include veterinary supplies, dental supplies, and diagnostic imaging. Patterson Companies Inc is headquartered in Minneapolis, Minnesota.
– Alfresa Holdings Corp ($TSE:2784)
Alfresa Holdings Corp is a Japanese pharmaceutical and medical equipment company with a market cap of 280.99B as of 2022. The company has a Return on Equity of 6.23%. Alfresa Holdings Corp is engaged in the research, development, manufacture, and sale of pharmaceuticals and medical equipment. The company’s products include drugs for the treatment of cancer, infectious diseases, and cardiovascular diseases; and medical devices for use in surgery, diagnosis, and treatment.
Summary
Henry Schein, Inc. has recently announced the acquisition of a majority stake in TriMed, an orthopedic device manufacturer. This move is expected to expand Henry Schein’s orthopedic device portfolio and provide increased access to the booming orthopedic market, which is a key growth sector for the company. The purchase is part of a strategic plan to diversify its product offerings and create more value for shareholders.
Additionally, the acquisition will enable Henry Schein to better compete with larger players in the orthopedic device space, such as Johnson & Johnson and Stryker. With this acquisition, Henry Schein is positioning itself to capitalize on the increasing demand for orthopedic devices and to better serve its customers.
Related Posts
Recent Posts
